Yuankai Shi

41PUBLICATIONS
39CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (41)

|Aug 27, 2026
Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial.

|Apr 26, 2026
Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study.

|Dec 01, 2025
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.

Yuankai Shi, Dongqing Lv, Weineng Feng

|Nov 28, 2025
Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000-2025).

Liling Huang, Haohua Zhu, Yuankai Shi

|May 06, 2025
First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial.

Yuankai Shi, Yi Ba, Junye Wang

|Dec 19, 2024
Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study.

Jianliang Yang, Yongping Song, Keshu Zhou

Pageof 7

Frequent Collaborators

3 joint publications

Xiaohong Han

3 joint publications

Xingsheng Hu

3 joint publications

Yu Feng

2 joint publications

Tongji Xie